# Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases

> **NCT03676257** · — · COMPLETED · sponsor: **Institut Bergonié** · enrollment: 20033 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Chemotherapy (exclusive)
- **DRUG:** Endocrine therapy (exclusive)
- **DRUG:** Combination of endocrine therapy and chemotherapy
- **DRUG:** Chemotherapy and targeted treatment
- **DRUG:** Combination of endocrine therapy and targeted treatment
- **DRUG:** Combination of chemotherapy, endocrine therapy and targeted treatment

## Key facts

- **NCT ID:** NCT03676257
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 20033 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03676257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03676257, "Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03676257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*